Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the safety and efficacy of anaplastic lymphoma kinase (ALK) inhibitors given as monotherapy to treat advanced ALK‐rearranged non‐small cell lung cancer (NSCLC).